EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Two sides of the same coin: Non-alcoholic fatty liver disease and atherosclerosis

Bo Zhu, Hao Wu, Kathryn S Li, Shahram Eisa-Beygi, Bandana Singh, Diane R Bielenberg, Wendong Huang, Hong Chen

Vascular Pharmacology · 2024

DOI: 10.1016/j.vph.2023.107249 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Vascular Pharmacology, 2024. Verfasst von Bo Zhu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Vascular Biology Program, Boston Children's Hospital, Department of Surgery, Harvard Medical School, Boston, MA, United States of America. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Atherosclerosis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 347 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, BLRD VA, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prevalence of non-alcoholic fatty liver disease (NAFLD) and atherosclerosis remain high, which is primarily due to widespread adoption of a western diet and sedentary lifestyle. NAFLD, together with advanced forms of this disease such as non-alcoholic steatohepatitis (NASH) and cirrhosis, are closely associated with atherosclerotic-cardiovascular disease (ASCVD). In this review, we discussed the association between NAFLD and atherosclerosis and expounded on the common molecular biomarkers underpinning the pathogenesis of both NAFLD and atherosclerosis. Furthermore, we have summarized the mode of function and potential clinical utility of existing drugs in the context of these diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseAtherosclerosisHumansLiver CirrhosisFibrosisBiomarkersLiver

Stichwörter der Autor:innen

AssociationAtherosclerosisBiomarkersNAFLDNASH

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Vascular Biology Program, Boston Children's Hospital, Department of Surgery, Harvard Medical School, Boston, MA, United States of America.
  • Department of Diabetes Complications and Metabolism, Arthur Riggs Diabetes and Metabolic Research Institute, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA 91010, United States of America.
  • Vascular Biology Program, Boston Children's Hospital, Department of Surgery, Harvard Medical School, Boston, MA, United States of America. Electronic address: hong.chen@childrens.harvard.edu.

Förderung

  • NHLBI NIH HHS
  • BLRD VA
  • National Institutes of Health

Zitieren

APA

Zhu, B., Wu, H., Li, K. S., Eisa-Beygi, S., Singh, B., Bielenberg, D. R., Huang, W., & Chen, H. (2024). Two sides of the same coin: Non-alcoholic fatty liver disease and atherosclerosis. Vascular Pharmacology. https://doi.org/10.1016/j.vph.2023.107249

Vancouver

Zhu B, Wu H, Li KS, Eisa-Beygi S, Singh B, Bielenberg DR, et al. Two sides of the same coin: Non-alcoholic fatty liver disease and atherosclerosis. Vascular Pharmacology. 2024. doi:10.1016/j.vph.2023.107249

BibTeX
@article{Zhu2024,
  author = {Zhu, Bo and Wu, Hao and Li, Kathryn S and Eisa-Beygi, Shahram and Singh, Bandana and Bielenberg, Diane R and Huang, Wendong and Chen, Hong},
  title = {Two sides of the same coin: Non-alcoholic fatty liver disease and atherosclerosis},
  journal = {Vascular Pharmacology},
  year = {2024},
  doi = {10.1016/j.vph.2023.107249}
}
Kostenlos starten →